★ INSERT COIN◆NOW PLAYING: VENTURES◆HIGH SCORE: $100M ARR◆★ NEW STAGE UNLOCKED: ABOUT ME◆PRESS START◆★ DEMO DAY 04:00:00◆
★ INSERT COIN◆NOW PLAYING: VENTURES◆HIGH SCORE: $100M ARR◆★ NEW STAGE UNLOCKED: ABOUT ME◆PRESS START◆★ DEMO DAY 04:00:00◆
◀ BACK TO FEED
NEWS★ LIFE SCIENCES / BIOTECHNOV 9, 2026

SRTD raises €31.5m for more selective mRNA therapies

An mRNA treatment needs to do its work in the right cells.

SRTD raises €31.5m for more selective mRNA therapies

An mRNA treatment needs to do its work in the right cells.

What happened

SRTD Biotech announced a €31.5m seed round, led by Mérieux Equity Partners with NRW.BANK and Boehringer Ingelheim Venture Fund as co-leads. The funding supports preclinical development of RNA therapies for cancer, autoimmune disease and fibrosis.

Why it matters

SRTD aims to activate therapeutic instructions selectively inside diseased cells. If successful, that approach could help limit unwanted activity in healthy tissue.

The bigger picture

This remains a development programme, not demonstrated clinical efficacy. Preclinical results, regulatory progress and eventual human data will determine whether the biological idea becomes a useful treatment.